These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35296412)

  • 1. In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery.
    Khuroo T; Mohamed EM; Dharani S; Immadi S; Nutan MTH; Lu D; Ali HI; Khan MA; Rahman Z
    J Pharm Sci; 2022 Aug; 111(8):2312-2321. PubMed ID: 35296412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations.
    Khuroo T; Dharani S; Mohamed EM; Immadi S; Wu Z; Khan MA; Lu D; Nehete P; Rahman Z
    Int J Pharm; 2021 Sep; 607():120889. PubMed ID: 34271151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
    Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
    AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
    McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport.
    Chu Y; Wong A; Chen H; Ji L; Qin C; Feng W; Stocks MJ; Gershkovich P
    Eur J Pharm Biopharm; 2023 Oct; 191():90-102. PubMed ID: 37634824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.
    Deodhar S; Sillman B; Bade AN; Avedissian SN; Podany AT; McMillan JM; Gautam N; Hanson B; Dyavar Shetty BL; Szlachetka A; Johnston M; Thurman M; Munt DJ; Dash AK; Markovic M; Dahan A; Alnouti Y; Yazdi A; Kevadiya BD; Byrareddy SN; Cohen SM; Edagwa B; Gendelman HE
    Nat Commun; 2022 Jun; 13(1):3226. PubMed ID: 35680875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.
    Kevadiya BD; Woldstad C; Ottemann BM; Dash P; Sajja BR; Lamberty B; Morsey B; Kocher T; Dutta R; Bade AN; Liu Y; Callen SE; Fox HS; Byrareddy SN; McMillan JM; Bronich TK; Edagwa BJ; Boska MD; Gendelman HE
    Theranostics; 2018; 8(1):256-276. PubMed ID: 29290806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV.
    K PD; D RD; S B; B Narayanan VH
    Sci Rep; 2022 Aug; 12(1):13907. PubMed ID: 35974065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubility and solution stability studies of different amino acid prodrugs of bromhexine.
    Aggarwal AK; Gupta M
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1319-27. PubMed ID: 22283553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
    Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
    Enoki Y; Kishi N; Sakamoto K; Uchiyama E; Hayashi Y; Suzuki N; Ito M; Taguchi K; Yokoyama Y; Kizu J; Matsumoto K
    Drug Metab Pharmacokinet; 2021 Apr; 37():100371. PubMed ID: 33556698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.
    Zhu J; Tian X; Shehu AI; McMahon DK; Ma X
    J Pharmacol Exp Ther; 2020 Jul; 374(1):38-43. PubMed ID: 32303561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
    Ciccullo A; Baldin G; Borghi V; Lagi F; Latini A; d'Ettorre G; Oreni L; Fusco P; Capetti A; Fabbiani M; Giacomelli A; Grimaldi A; Madeddu G; Sterrantino G; Mussini C; Di Giambenedetto S
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.